|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-2-18
|
|
pubmed:abstractText |
We determined the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when infused on days 1, 8, and 15 of a 28-day cycle in advanced solid tumor patients. We also characterized the pharmacokinetics of 17-AAG, its effect on chaperone and client proteins, and whether cytochrome P450 (CYP) 3A5 and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphisms affected 17-AAG disposition or toxicity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/17-(allylamino)-17-demethoxygeldanam...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzoquinones,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/HSP90 Heat-Shock Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lactams, Macrocyclic,
http://linkedlifedata.com/resource/pubmed/chemical/NAD(P)H Dehydrogenase (Quinone),
http://linkedlifedata.com/resource/pubmed/chemical/NQO1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Rifabutin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AdjeiAlexA,
pubmed-author:AdjeiAraba AAA,
pubmed-author:AmesMatthewM,
pubmed-author:AthertonPamelaP,
pubmed-author:CroghanGaryG,
pubmed-author:ErlichmanCharlesC,
pubmed-author:GoetzMatthew PMP,
pubmed-author:ReidJoelJ,
pubmed-author:SafgrenStephanieS,
pubmed-author:SalazaarSandraS,
pubmed-author:SloanJeffJ,
pubmed-author:StensgardBridgetB,
pubmed-author:ToftDavidD,
pubmed-author:VasileVladV
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1078-87
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15718306-Adult,
pubmed-meshheading:15718306-Aged,
pubmed-meshheading:15718306-Antineoplastic Agents,
pubmed-meshheading:15718306-Benzoquinones,
pubmed-meshheading:15718306-Biological Markers,
pubmed-meshheading:15718306-Cytochrome P-450 CYP3A,
pubmed-meshheading:15718306-Cytochrome P-450 Enzyme System,
pubmed-meshheading:15718306-Drug Administration Schedule,
pubmed-meshheading:15718306-Female,
pubmed-meshheading:15718306-HSP90 Heat-Shock Proteins,
pubmed-meshheading:15718306-Humans,
pubmed-meshheading:15718306-Lactams, Macrocyclic,
pubmed-meshheading:15718306-Male,
pubmed-meshheading:15718306-Maximum Tolerated Dose,
pubmed-meshheading:15718306-Middle Aged,
pubmed-meshheading:15718306-NAD(P)H Dehydrogenase (Quinone),
pubmed-meshheading:15718306-Neoplasms,
pubmed-meshheading:15718306-Polymorphism, Genetic,
pubmed-meshheading:15718306-Rifabutin
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
|
|
pubmed:affiliation |
Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
